Overview 

This track offers practitioners in the data-driven, dynamic, disruptive field of structural heart disease the opportunity to catch-up on all the new patient choices that have emerged over the past 12 months. The skills and knowledge gained will help interventionalists hone the expertise necessary for practice today and prepare for the evolving field of tomorrow.  

Taking a tiered approach to learning, the agenda expands out from the basics to cover the major, upcoming developments in the field. The agenda is quality-led and patient-centered, focusing on the need for training and best practices in all things technical in the cath lab.  

Target Audience 

This track offers step-by-step technical instruction for those early in their career and more experienced operators wanting to add to their skillset.  

Learning Objectives

After attending SCAI Scientific sessions, the learner will be able to: 

• Discuss the evidence behind transcatheter aortic valve replacement for unique patient populations (i.e. long life expectancy;  low-output, low gradient; borderline femoral access) 
• Appraise the data on transcatheter mitral valve repair and replacement and apply to challenging patient selection scenarios  
• Describe approaches to controversial patient presentations for left atrial appendage closure, and the role of clinical trials in informing strategic decisions (i.e. LAA removal at time of surgery; LAAO for patients without history of bleeding) 
• Explain the unmet need for the treatment of tricuspid regurgitation and list ongoing trials in transcatheter repair and replacement 
• Compare and contrast best practices in addressing disparities in the interventional cardiology workforce, and how diverse representation and leadership impacts patient selection for structural heart therapies and practice and clinical trials 

Topics Covered 

Speakers are chosen not only for their expertise, but also their skills as teachers and educators, will present a series of practical, easy-to-follow sessions on an array of topics, and clinical trial leaders will discuss the latest advances and research shaping the field.